Business Wire

VA-REGULA-FORENSICS

14.9.2023 09:01:34 CEST | Business Wire | Press release

Share
Regula Repeatedly Named a Representative Vendor in Gartner Market Guide for Identity Verification

The identity verification industry has evolved significantly in recent years, expanding its scope beyond traditional Know Your Customer (KYC) processes. As IDV is becoming the new norm, more identity verification providers are vying for the attention of potential customers.

While the market is becoming a buyer’s market, it can also be confusing because of the many seemingly similar offers. As Gartner notes, “It is challenging for end-user organizations to select a vendor in a crowded market. Many tend to simply select vendors with experience and presence in their country or region.” However, it’s more important than ever before to have comprehensive selection criteria when choosing a solution.

The two pillars of identity verification: Document authenticity and liveness check

In the era of digital nomadism, it’s an advantage for a vendor to have global coverage of supported IDs. Not only is it a plus for user experience, but it also provides qualitative attributes for effective fraud prevention.

Also, remote interactions are paramount in most scenarios. A proper solution should offer an extensive set of document verification checks, from automatic document type recognition to NFC-based verification (the most trustworthy method). Concerning the latter, an effective solution should allow re-verification of electronic chips by processing results on a server, thus eliminating the risk of accepting a tampered ID.

As for binding the ID to the actual individual, it may already be not enough to ask users to take selfies (passive liveness check). Organizations need to be able to detect various biometric fraud, including injection attacks, and be able to compare live biometrics with the photo on the document and the data encoded in the chip embedded in the ID.

All in all, it’s crucial for a vendor to deliver a complete verification solution that tackles everything mentioned above. These key tasks are covered by Regula’s products acknowledged in the report—Regula Document Reader SDK and Regula Face SDK. Together, they form a solid future-proof foundation for reliable identity verification.

Beyond the basics

Given the evolving landscape of security challenges and the growing demand for comprehensive solutions, organizations are looking for tools that can offer more than just the basics. Vendors are expected to stand out by adding more value through augmenting core capabilities with novel implementation approaches and the ability to handle AI-enabled attack vectors.

According to Regula’s latest survey, in the past year, 37% of organizations encountered incidents of deepfake voice fraud, while 29% fell victim to deepfake videos. The increasing accessibility of artificial intelligence technology for crafting deepfakes is amplifying these risks, posing a significant challenge for both businesses and individuals.

Regula has taken a proactive approach to fortifying defenses against this threat by investing in a forward-looking roadmap. "When it comes to detecting deepfakes, we believe that neural networks can be valuable for defensive purposes, as long as they come with other anti-fraud measures that focus on physical and dynamic parameters,” says Henry Patishman, VP of Identity Verification Solutions at Regula. “These include face liveness checks, document liveness checks, optically variable security elements, and more. It's still challenging to create deepfakes that show the expected dynamic behavior. Verifying the liveness of an object can provide a crucial advantage against fraudsters. Additionally, cross-referencing user information with biometric checks and recent transaction history can enhance the verification process."

*Gartner, Market Guide for Identity Verification, Akif Khan, 7 September 2023

About Gartner

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Proofing and Affirmation in 2022. Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230915253195/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release

New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency

NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release

Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,

REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release

Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye